Discovery of new chemical entities as potential leads against Mycobacterium tuberculosis

Bioorg Med Chem Lett. 2016 Dec 15;26(24):5916-5919. doi: 10.1016/j.bmcl.2016.11.003. Epub 2016 Nov 2.

Abstract

A series of biheterocyclic (1H-indole, benzofuran, pyrazolo[1,5-a]pyrimidine, pyrazolo[1,5-a]pyrimidin-5(4H)-one, imidazo[2,1-b]thiazole and pyrazolo[5,1-b]thiazole) derivatives were synthesized and evaluated for their anti-tubercular activities. The imidazo[2,1-b]thiazoles 9a-c and pyrazolo[5,1-b]thiazoles 10a-c exhibited promising anti-tubercular activity in varying degrees. Especially, the 2,6-dimethylpyrazolo[5,1-b]thiazole 10a exhibited strong suppressing function against H37Ra strain with MIC value of 0.03μg/mL. Compound 10a also displayed good pharmacokinetic profiles with oral bioavailability (F) of 41.7% and a half-life of 13.4h. Furthermore, 10a significantly reduced the bacterial burden in an autoluminescent H37Ra infected mouse model, suggesting its promising potential for development of anti-tubercular drugs.

Keywords: Anti-tubercular agent; Imidazo[21-b]thiazole; Pyrazolo[51-b]thiazole; Scaffold hopping.

MeSH terms

  • Administration, Oral
  • Animals
  • Antitubercular Agents / administration & dosage
  • Antitubercular Agents / chemistry
  • Antitubercular Agents / pharmacology*
  • Biological Availability
  • Chlorocebus aethiops
  • Disease Models, Animal
  • Dose-Response Relationship, Drug
  • Drug Discovery*
  • Mice
  • Molecular Structure
  • Mycobacterium tuberculosis / drug effects*
  • Rats
  • Structure-Activity Relationship
  • Tuberculosis / drug therapy*
  • Vero Cells

Substances

  • Antitubercular Agents